The unique pharmacokinetic properties of TXA-709 may allow it to effectively treat staphylococcus aureus infections, including MRSA, while reducing the possibility of patients developing a resistance to the antibiotic. Animal model studies have shown that TXA-709, a drug being developed by TAXIS Pharmaceuticals, is more effective at combatting staph infections than the current standards of … Continue reading TXA-709 Retains Strong Bactericidal Activity Against S. Aureus